NASDAQ: ICCCImmucell Corp Stock
$5.05+0.00 (+0%)
Updated Apr 18, 2024
ICCC Price
$5.05
Fair Value Price
N/A
Market Cap
$39.14M
52 Week Low
$4.26
52 Week High
$6.05
P/E
-6.73x
P/B
1.57x
P/S
2.26x
PEG
N/A
Dividend Yield
N/A
Revenue
$17.47M
Earnings
-$5.77M
Gross Margin
22.1%
Operating Margin
-33.02%
Profit Margin
-33.1%
Debt to Equity
0.75
Operating Cash Flow
-$5M
Beta
0.14
Next Earnings
May 10, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ICCC Overview
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ICCC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ICCC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ICCC is good value based on its book value relative to its share price (1.57x), compared to the US Biotechnology industry average (5.76x)
P/B vs Industry Valuation
ICCC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ICCC due diligence checks available for Premium users.
Be the first to know about important ICCC news, forecast changes, insider trades & much more!
ICCC News
Valuation
ICCC fair value
Fair Value of ICCC stock based on Discounted Cash Flow (DCF)
Price
$5.05
Fair Value
$6.12
Undervalued by
17.42%
ICCC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ICCC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.73x
Industry
15.68x
Market
41.33x
ICCC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.57x
Industry
5.76x
ICCC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ICCC's financial health
Profit margin
Revenue
$5.1M
Net Income
-$1.1M
Profit Margin
-22.4%
ICCC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ICCC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$43.8M
Liabilities
$18.8M
Debt to equity
0.75
ICCC's short-term assets ($11.47M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ICCC's long-term liabilities ($14.62M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ICCC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ICCC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$723.1k
Investing
$33.8k
Financing
-$321.4k
ICCC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ICCC vs Biotech Stocks
Immucell Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.